John McHutchison

Gilead Sciences, Inc. (NASDAQ: GILD) is facing another setback, as its non-alcoholic steatohepatitis, or NASH, candidate Selonsertib flunked in a late-stage study. Stellar Trial's Dimmed Results Gilead said the STELLAR-4 study that evaluated the safety and efficacy of Selonsertib in patients...